Literature DB >> 2027492

Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin.

F H Bahls1, J Ozuna, D E Ritchie.   

Abstract

We describe a retrospective analysis of the frequency of adverse interactions between calcium channel blockers and anticonvulsant drugs (phenytoin and carbamazepine) in a series of 43 patients. Ten patients receiving carbamazepine and three patients receiving phenytoin exhibited symptoms or signs of toxicity. Toxicity occurred with both diltiazem and verapamil, but not with nifedipine. These results emphasize the need for careful clinical and laboratory monitoring of patients receiving both classes of medication.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2027492     DOI： 10.1212/wnl.41.5.740

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 2.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

3.  Choice of initial antiepileptic drug for older veterans: possible pharmacokinetic drug interactions with existing medications.

Authors:  Mary Jo V Pugh; Anne C Vancott; Michael A Steinman; Eric M Mortensen; Megan E Amuan; Chen-Pin Wang; Janice E Knoefel; Dan R Berlowitz
Journal:  J Am Geriatr Soc       Date:  2010-03       Impact factor: 5.562

Review 4.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 5.  Drug Interactions in Neurocritical Care.

Authors:  Brian Spoelhof; Salia Farrokh; Lucia Rivera-Lara
Journal:  Neurocrit Care       Date:  2017-10       Impact factor: 3.210

6.  Hypertension, seizures, and epilepsy: a review on pathophysiology and management.

Authors:  Sara Gasparini; Edoardo Ferlazzo; Chiara Sueri; Vittoria Cianci; Michele Ascoli; Salvatore M Cavalli; Ettore Beghi; Vincenzo Belcastro; Amedeo Bianchi; Paolo Benna; Roberto Cantello; Domenico Consoli; Fabrizio A De Falco; Giancarlo Di Gennaro; Antonio Gambardella; Gian Luigi Gigli; Alfonso Iudice; Angelo Labate; Roberto Michelucci; Maurizio Paciaroni; Pasquale Palumbo; Alberto Primavera; Ferdinando Sartucci; Pasquale Striano; Flavio Villani; Emilio Russo; Giovambattista De Sarro; Umberto Aguglia
Journal:  Neurol Sci       Date:  2019-05-04       Impact factor: 3.307

Review 7.  Intracellular Signaling Cascades in Bipolar Disorder.

Authors:  Gregory H Jones; Carola Rong; Aisha S Shariq; Abhinav Mishra; Rodrigo Machado-Vieira
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 8.  Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org).

Authors:  Pieter G Postema; Christian Wolpert; Ahmad S Amin; Vincent Probst; Martin Borggrefe; Dan M Roden; Silvia G Priori; Hanno L Tan; Masayasu Hiraoka; Josep Brugada; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2009-07-08       Impact factor: 6.343

Review 9.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

Review 10.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.